{"transactions":[{"id":733021,"issuer":{"id":275,"kind":"organization","name":"Zenas BioPharma, Inc.","symbol":"ZBIO"},"owners":[{"id":37074,"kind":"person","name":"Boylan James P","position":1,"cik":"0001953094","reported_name":"Boylan James P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-17T22:01:20.000Z","date":"2026-06-15","kind":"grant","planned":false,"acquired":true,"shares":18500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 100% of the underlying shares of common stock on June 15, 2027, the first anniversary of the vesting commencement date, subject to continued service."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The reporting person holds the stock option, and the shares underlying the option, for the benefit of Enavate Sciences, L.P. Accordingly, the reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, if any."}],"balance_after":18500,"derivative":{"exercise_price":18.71,"expiration_date":"2036-06-15","underlying":"Common Stock","underlying_shares":18500},"source":{"system":"sec-edgar","filing":"0001104659-26-075252","document":"tm2618042-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1953094/000110465926075252/tm2618042-4_4seq1.xml","form_type":"4"}},{"id":739718,"issuer":{"id":4219,"kind":"organization","name":"Immunome Inc.","symbol":"IMNM"},"owners":[{"id":37074,"kind":"person","name":"Boylan James P","position":1,"cik":"0001953094","reported_name":"Boylan James P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2026-06-12T21:51:52.000Z","date":"2026-06-10","kind":"grant","planned":false,"acquired":true,"shares":9897,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Mr. Boylan has agreed to receive and hold for the benefit of Enavate Sciences, LP, any securities granted to him for his service as a director on the Company's board of directors. As such, Mr. Boylan disclaims beneficial ownership of, and all right, title and interest in, the reported securities."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests in four equal quarterly installments, commencing from June 10, 2026 until the one-year anniversary thereafter, occurring on the same day of each succeeding fiscal quarter, subject to the Mr. Boylan's continuous service with the Company on each respective vesting date."}],"balance_after":9897,"derivative":{"exercise_price":18.16,"expiration_date":"2036-06-09","underlying":"Common Stock","underlying_shares":9897},"source":{"system":"sec-edgar","filing":"0001953094-26-000002","document":"form4-06122026_090648.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1472012/000195309426000002/form4-06122026_090648.xml","form_type":"4"}},{"id":951648,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":37074,"kind":"person","name":"Boylan James P","position":1,"cik":"0001953094","reported_name":"Boylan James P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-05T21:32:36.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This grant vests in full upon the earlier of (i) June 10, 2026 or (ii) the date of the next annual meeting of the Company's stockholders."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The Reporting Person is a member of Enavate Sciences, LP (\"Enavate\"). Pursuant to an agreement with Enavate, the Reporting Person is obligated to transfer any securities issued under any stock options or other awards, or the economic benefit thereof, to Enavate, which will in turn ensure that such securities or economic benefits are provided to Enavate"}],"balance_after":90000,"derivative":{"exercise_price":5.17,"expiration_date":"2036-01-02","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001171843-26-000054","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184326000054/ownership.xml","form_type":"4"}},{"id":1099870,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":37074,"kind":"person","name":"Boylan James P","position":1,"cik":"0001953094","reported_name":"Boylan James P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-27T20:03:21.000Z","date":"2025-06-25","kind":"grant","planned":false,"acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option vest in their entirety on the earlier of the first anniversary of the grant date or the date of the issuer's next annual meeting of stockholders, subject to continued service to the issuer's board of directors through the applicable vesting date."}],"balance_after":9000,"derivative":{"exercise_price":1.56,"expiration_date":"2035-06-24","underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001736730-25-000061","document":"wk-form4_1751054595.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1736730/000173673025000061/wk-form4_1751054595.xml","form_type":"4"}},{"id":1113266,"issuer":{"id":4219,"kind":"organization","name":"Immunome Inc.","symbol":"IMNM"},"owners":[{"id":37074,"kind":"person","name":"Boylan James P","position":1,"cik":"0001953094","reported_name":"Boylan James P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2025-06-12T21:00:00.000Z","date":"2025-06-10","kind":"grant","planned":false,"acquired":true,"shares":18864,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Mr. Boylan has agreed to receive and hold for the benefit of Enavate Sciences, LP, any securities granted to him for his service as a director on the Company's board of directors. As such, Mr. Boylan disclaims beneficial ownership of, and all right, title and interest in, the reported securities."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests in four quarterly installments, commencing from June 10, 2025 until the one-year anniversary thereafter, occurring on the same day of each succeeding fiscal quarter, subject to Mr. Boylan's continuous service with the Company on each respective vesting date."}],"balance_after":18864,"derivative":{"exercise_price":9.57,"expiration_date":"2035-06-09","underlying":"Common Stock","underlying_shares":18864},"source":{"system":"sec-edgar","filing":"0001415889-25-016991","document":"form4-06122025_080657.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1472012/000141588925016991/form4-06122025_080657.xml","form_type":"4"}},{"id":1112769,"issuer":{"id":275,"kind":"organization","name":"Zenas BioPharma, Inc.","symbol":"ZBIO"},"owners":[{"id":37074,"kind":"person","name":"Boylan James P","position":1,"cik":"0001953094","reported_name":"Boylan James P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-12T20:36:42.000Z","date":"2025-06-10","kind":"grant","planned":false,"acquired":true,"shares":18500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 100% of the underlying shares of common stock on June 10, 2026, the first anniversary of the vesting commencement date, subject to continued service."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The reporting person holds the stock option, and the shares underlying the option, for the benefit of Enavate Sciences, LP. Accordingly, the reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, if any."}],"balance_after":18500,"derivative":{"exercise_price":11.94,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":18500},"source":{"system":"sec-edgar","filing":"0001104659-25-058935","document":"tm2517684-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1953094/000110465925058935/tm2517684-8_4seq1.xml","form_type":"4"}},{"id":1269699,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":37074,"kind":"person","name":"Boylan James P","position":1,"cik":"0001953094","reported_name":"Boylan James P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-13T22:05:34.000Z","date":"2025-02-11","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest over 48 substantially equal monthly installments starting March 11, 2025."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The Reporting Person is a member of Enavate Sciences, LP (\"Enavate\"). Pursuant to an agreement with Enavate, the Reporting Person is obligated to transfer any securities issued under any stock options or other awards, or the economic benefit thereof, to Enavate, which will in turn ensure that such securities or economic benefits are provided to Enavate."}],"balance_after":40000,"derivative":{"exercise_price":3.65,"expiration_date":"2035-02-11","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001171843-25-000823","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184325000823/ownership.xml","form_type":"4"}},{"id":1406246,"issuer":{"id":275,"kind":"organization","name":"Zenas BioPharma, Inc.","symbol":"ZBIO"},"owners":[{"id":37074,"kind":"person","name":"Boylan James P","position":1,"cik":"0001953094","reported_name":"Boylan James P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-09-17T00:55:32.000Z","date":"2024-09-12","kind":"grant","planned":false,"acquired":true,"shares":37000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Mr. Boylan has agreed to receive and hold for the benefit of, Enavate Sciences, LP, any securities granted to him for his service as a director on the Issuer's board of directors. As such, Mr. Boylan disclaims beneficial ownership of, and all right, title and interest in, the option and the shares issuable upon exercise thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests in equal annual installments over three years beginning on September 12, 2025, the first anniversary of the vesting commencement date, subject to continued service."}],"balance_after":37000,"derivative":{"exercise_price":17,"expiration_date":"2034-09-11","underlying":"Common Stock","underlying_shares":37000},"source":{"system":"sec-edgar","filing":"0001104659-24-100332","document":"tm2424157-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1953094/000110465924100332/tm2424157-7_4seq1.xml","form_type":"4"}},{"id":1475143,"issuer":{"id":4219,"kind":"organization","name":"Immunome Inc.","symbol":"IMNM"},"owners":[{"id":37074,"kind":"person","name":"Boylan James P","position":1,"cik":"0001953094","reported_name":"Boylan James P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2024-06-19T01:01:18.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":11333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Mr. Boylan has agreed to receive and hold for the benefit of Enavate Sciences, LP, any securities granted to him for his service as a director on the Company's board of directors. As such, Mr. Boylan disclaims beneficial ownership of, and all right, title and interest in, the reported securities."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest in 4 quarterly installments, commencing from June 13, 2024 until the one year anniversary thereafter, occurring on the same day of each succeeding fiscal quarter, subject to continued service with the Company on each respective vesting date."}],"balance_after":11333,"derivative":{"exercise_price":16.04,"expiration_date":"2034-06-12","underlying":"Common Stock","underlying_shares":11333},"source":{"system":"sec-edgar","filing":"0001415889-24-017526","document":"form4-06192024_010614.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1472012/000141588924017526/form4-06192024_010614.xml","form_type":"4"}},{"id":1584287,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":37074,"kind":"person","name":"Boylan James P","position":1,"cik":"0001953094","reported_name":"Boylan James P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-11T14:12:03.000Z","date":"2024-03-08","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest over 48 substantially equal monthly installments starting April 8, 2024."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The Reporting Person is a member of Enavate Sciences, LP (\"Enavate\"). Pursuant to an agreement with Enavate, the Reporting Person has agreed to receive and hold for the benefit of Enavate any securities issued under any stock options or other awards granted to him for his services as a director on the Issuer's board of directors. As such, the Reporting Person disclaims beneficial ownership of, and all right, title and interest in, the reported securities."}],"balance_after":40000,"derivative":{"exercise_price":1.96,"expiration_date":"2034-03-07","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001171843-24-001275","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184324001275/ownership.xml","form_type":"4"}},{"id":1753121,"issuer":{"id":4219,"kind":"organization","name":"Immunome Inc.","symbol":"IMNM"},"owners":[{"id":37074,"kind":"person","name":"Boylan James P","position":1,"cik":"0001953094","reported_name":"Boylan James P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2023-10-31T22:32:27.000Z","date":"2023-10-27","kind":"grant","planned":false,"acquired":true,"shares":41538,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Mr. Boylan waived the initial grant provided for under the Company's non-employee director compensation policy in effect on the date he joined the Company's board of directors pending the adoption of an amended and restated non-employee director compensation policy (the \"New NED Compensation Policy\"). On October 27, 2023, the compensation committee of the Company's board of directors adopted and approved the New NED Compensation Policy. The above reflects Mr. Boylan's initial grant under the New NED Compensation Policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest in 12 quarterly installments over three years, commencing on October 2, 2023 and continuing thereafter on the same day of each succeeding fiscal quarter, subject to continued service with the Company on each respective vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Mr. Boylan has agreed to receive and hold for the benefit of Enavate Sciences, LP, any securities granted to him for his service as a director on the Company's board of directors. As such, Mr. Boylan disclaims beneficial ownership of, and all right, title and interest in, the reported securities."}],"balance_after":41538,"derivative":{"exercise_price":8.73,"expiration_date":"2033-10-26","underlying":"Common Stock","underlying_shares":41538},"source":{"system":"sec-edgar","filing":"0001209191-23-053983","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1472012/000120919123053983/doc4.xml","form_type":"4"}}]}